-
1
Mucocutaneous Adverse Events in Patients With Cancer Treated with the Highly Selective RET Kinase Inhibitor Selpercatinib (LOXO-292)
Published 2025-03-01Subjects: “…Selpercatinib…”
Get full text
Article -
2
Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case
Published 2025-01-01Subjects: Get full text
Article -
3
Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer
Published 2025-01-01Subjects: Get full text
Article -
4
Research on detection methods of related substances and degradation products of the antitumor drug selpercatinib
Published 2025-01-01Subjects: “…selpercatinib…”
Get full text
Article -
5
-
6
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
Published 2025-01-01Subjects: Get full text
Article